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Current drugs used to treat proteinuric disorders of the kidney have been borrowed
from other branches of medicine, and are only partially effective. The discovery of a
central, mechanistic role played by two different forms of the secreted glycoprotein
angiopoietin-like 4 (Angptl4) in human and experimental glomerular disease has opened
new treatment avenues. Localized upregulation of a hyposialylated form (lacks sialic acid
residues) of Angptl4 secreted by podocytes induces the cardinal morphological and clinical
manifestations of humanminimal change disease, and is also being increasingly recognized
as a signiﬁcant contributor toward proteinuria in experimental diabetic nephropathy. Oral
treatment with low doses of N -acetyl-D-mannosamine, a naturally occurring precursor of
sialic acid, improves sialylation of Angptl4 in vivo, and reduces proteinuria by over 40%. By
contrast, a sialylated circulating form of Angptl4, mostly secreted from skeletal muscle,
heart and adipose tissue in all major primary glomerular diseases, reduces proteinuria
while also causing hypertriglyceridemia. Intravenous administration of recombinant human
Angptl4 mutated to avoid hypertriglyceridemia and cleavage has remarkable efﬁcacy in
reducing proteinuria by as much as 65% for 2 weeks after a single low dose. Both interven-
tions are mechanistically relevant, utilize naturally occurring pathways, and represent new
generation therapeutic agents for chronic kidney disease related to glomerular disorders.
Keywords: diabetic nephropathy, focal and segmental glomerulosclerosis, proteinuria, angiopoietin-like 4,
therapeutics, minimal change disease, N acetyl D mannosamine, sialic acids
Current therapy for kidney disease in general and kidney disease
related to proteinuric disorders in speciﬁc has relied upon the
use of agents borrowed from other ﬁelds. One category of
agents used to treat glomerular disease have immunosuppres-
sive properties, and include glucocorticoids, cyclophosphamide,
azathioprine, chlorambucil, mycophenolate mofetil, cyclosporine,
tacrolimus, and the anti-CD20 antibody. Another category con-
tains drugs used for supportive therapy, including a variety of
diuretics and agents that block the renin angiotensin system at
different levels, like angiotensin converting enzyme inhibitors,
angiotensin receptor blockers, spironolactone, and more recently,
renin inhibitors like aliskiren. The traditional rationale behind
the use of the ﬁrst category of drugs was their immunosuppres-
sive effect, but it has become clear over the past decade that
many of these drugs have direct effects on resident glomeru-
lar cells (Faul et al., 2008; Clement et al., 2011). The concept
of blocking the renin angiotensin system ﬂourished in the 20th
century, since at least partial efﬁcacy in reducing proteinuria
and slowing the progression of kidney disease was noted, and
there were no other known pathogenic pathways that could be
targeted.
EMERGENCE OF ANGIOPOIETIN-LIKE 4 AS A THERAPEUTIC
AGENT AND TARGET
The 21st century witnessed a revolution in the identiﬁcation of
genes and proteins related to glomerular diseases, that can now
be organized into drug targetable disease pathways. Even though
these pathways are incomplete, it does not preclude the scientiﬁc
community from developing new and more speciﬁc treatment
strategies, if suitable end points are noted in experimental stud-
ies. The overall approach in our laboratory has been to identify a
protein involved in the pathogenesis of proteinuria and at least
one additional component of nephrotic syndrome (Figure 1).
By grouping hypoalbuminemia with proteinuria and lipiduria
with hyperlipidemia, we used three functional components of
nephrotic syndrome for our studies: proteinuria, hyperlipidemia
(hypertriglyceridemia and hypercholesterolemia), and edema.
Once a gene involved in at least two of these three components was
identiﬁed, its molecular pathways were dissected, and therapeutic
strategies were developed speciﬁcally to reduce proteinuria with-
out aggravating the other components of nephrotic syndrome.
During discovery phase experiments (Liu et al., 2006; Clement
et al., 2011) conducted in 2002 using glomeruli from highly pro-
teinuric rats, we noted that the most highly upregulated gene
out of forty differentially expressed genes fulﬁlled this criteria.
This gene, angiopoietin-like 4 (Angptl4), had just been cloned
(Kersten et al., 2000;Yoon et al., 2000) and identiﬁed as a PPAR tar-
get gene, and recombinant Angptl4 protein was shown to induce
hypertriglyceridemia when injected into rodents (Yoshida et al.,
2002).
Initial studies revealed increased podocyte expression of
Angptl4 in human and experimental minimal change disease
(MCD), transient upregulation after the onset of proteinuria in
experimental membranous nephropathy (MN), and no change in
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FIGURE 1 | Overall strategy for development of novel therapeutic modalities to treat proteinuria and chronic kidney disease.
podocyte expression in non-HIV collapsing glomerulopathy (CG)
and focal and segmental glomerulosclerosis (FSGS) (Clement
et al., 2011). Further investigation revealed two types of Angptl4
protein in nephrotic syndrome (Figure 2): (a) A hyposialylated
form secreted from podocytes in MCD (Clement et al., 2011),
and later also noted in glomeruli of Zucker Diabetic Fatty rats
(Chugh,2011b). Conversionof this highpI hyposialylatedAngptl4
to sialylated neutral pI Angptl4 in vivo using the sialic acid pre-
cursor N-acetyl-D-mannosamine (ManNAc) reduces proteinuria
(Clement et al., 2011), and this improvement in proteinuria was
noted in rats with MCD (Clement et al., 2011) and diabetic
nephropathy (Chugh, 2011b). (b) A neutral pI sialylated form
of Angptl4 is increased in the circulation of patients with MCD,
MN, FSGS, and CG (Clement et al., 2014). Most of this sialy-
lated protein is secreted from skeletal muscle, heart and adipose
tissue when proteinuria reaches nephrotic range in an attempt
to reduce proteinuria through glomerular endothelial binding,
but also induces hypertriglyceridemia via inhibition of lipopro-
tein lipase (LPL). Mutant forms of this protein generated by
our lab reduce proteinuria without affecting plasma triglyceride
levels in nephrotic rats with FSGS and diabetic nephropathy
(Clement et al., 2014).
Since circulating Angptl4 is a major molecular mediator of
nephrotic syndrome due to a variety of glomerular diseases, it
is an ideal candidate for a parenteral once-a-month therapeutic
agent to treat proteinuric disorders that cause chronic kidney dis-
ease. On the other hand, ManNAc is orally bioavailable, and has
enormous potential in low doses to treat diabetic nephropathy
and as a maintenance drug to prevent MCD relapse after the ﬁrst
episode is treated with glucocorticoids.
RATIONALE BEHIND SIALYLATION BASED THERAPEUTICS
FOR MCD AND DIABETIC NEPHROPATHY
Our laboratory described the upregulation of podocyte secreted
Angptl4 in human and experimental MCD, and developed a trans-
genic rat model, the NPSH2-Angptl4 rat, to replicate its effects
(Clement et al., 2011). These rats develop most of the classic fea-
tures of human MCD, including nephrotic range and selective
proteinuria, diffuse effacement of podocyte foot processes, loss of
glomerular basement membrane charge, and studies in the PAN
model showed that the gene is glucocorticoid sensitive in vivo.
Podocytes in NPHS2-Angptl4 transgenic rats, and PAN rats in the
early glucocorticoid-sensitive phase overproduce a hyposialylated
form of Angptl4. Treating these rats with ManNAc improves the
sialylation of Angptl4 in vivo, and reduces proteinuria by at least
40%. By contrast, 2D gel migration pattern of podocalyxin, a sia-
lylated structural protein expressed in podocytes, is not altered in a
manner to suggest an effect on structural proteins (Clement et al.,
2011). Subsequent studies show the existence of high pI hyposialy-
lated Angptl4 in glomeruli of rats with diabetic nephropathy, and
treatment of Zucker Diabetic Fatty rats with ManNAc resulted in
a signiﬁcant decline in proteinuria (Chugh, 2011b). These studies
suggest that even though diabetic nephropathy is a multicom-
ponent disease (i.e., has features of many primary glomerular
diseases, and more), the contribution of hyposialylated Angptl4
to this disorder is prominent, and warrants therapy. Molecular
pathways leading up to sustained Angptl4 upregulation in MCD,
and not in other primary glomerular diseases, have not as yet been
published.
There are several factors that contribute toward the genera-
tion of hyposialylated Angptl4 in podocytes and its susceptibility
to treatment with sialic acid precursors (Clement et al., 2011;
Chugh et al., 2012). Sialylation of proteins is a common event
in human cells, and sialic acid is most commonly incorporated
at O- and N- glycosylation sites of glycoproteins, and in gly-
cosphingolipids (gangliosides). It is important to understand the
differences between structural and secreted proteins in terms of
their requirement for sialic acid. A substantial amount of sialic
acid in cells is recycled (Figure 3), which reduces tremendously
the burden for de novo sialic acid synthesis (Bertozzi et al., 2009).
This recycled sialic acid likely comesmostly from structural, and to
a lesser extent, endocytosed proteins, since sialylation of secreted
proteins represents a net loss of total cellular sialic acid content.
This net loss must then be made up by de novo sialic acid synthe-
sis. Humans synthesize sialic acid from glucose (Figure 3), since
there is no major nutritional source of N-acetylneuraminic acid
(NANA/Neu5Ac), the predominant form of sialic acid present in
humans (Varki and Schauer, 2009). Animals convert NANA into
N-glycolylneuraminic acid (NGNA/Neu5Gc) using the enzyme
NANA hydroxylase, which is non-functional in humans due to
an exon deletion/frame shift mutation (Chou et al., 1998). Under
most circumstances, NGNA is not incorporated into human pro-
teins, thereby excluding diet as a source of sialic acid in humans.
Some organs, like liver and adipose tissue, that produce large num-
ber of secreted proteins have a very active sialic acid biosynthesis
pathway, and therefore, in the current context, secrete sialylated
Angptl4 into the circulation normally and during times of high
demand (e.g., fasting, nephrotic syndrome). Podocytes likely have
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FIGURE 2 | Pathobiology of Angptl4 in nephrotic syndrome. In
minimal change disease (MCD), podocytes secrete a hyposialylated form
that remains restricted to the kidney and induces proteinuria, and a
sialylated form that enters the circulation. Treatment with glucocorticoids
reduces podocyte Angptl4 upregulation. In all forms of primary
glomerular disease like membranous nephropathy (MN), focal and
segmental glomerulosclerosis (FSGS), non-HIV collapsing glomerulopathy
(CG), and MCD, peripheral organs (mostly skeletal muscle, heart and
adipose tissue) secrete the circulating, sialylated form of Angptl4.
Treatment with glucocorticoids, PPAR agonists and free fatty acids
increase peripheral organ Angptl4 secretion. Circulating Angptl4 binds to
glomerular endothelial αvβ5 integrin to reduce proteinuria, or inactivates
endothelium bound lipoprotein lipase (LPL) in skeletal muscle, heart and
adipose tissue to reduce hydrolysis of plasma triglycerides to free fatty
acids (FFAs), resulting in hypertriglyceridemia. Some Angptl4 and LPL
are lost in the urine. Adapted from Clement et al. (2014).
a less active sialic acid biosynthesis pathway (Chugh et al., 2012),
and in the setting of severe upregulation of Angptl4 in MCD and
diabetic nephropathy, this pathway is unable to cope with high
demand, despite a slight increase in the expression of the rate
limiting enzyme GlcNAc 2-epimerase (GNE) in both disorders.
This results in the secretion of a combination of hyposialylated
and sialylated Angptl4 from podocytes. An additional factor in
this equation in podocytes may be limited activity of a class
of enzymes that transfers sialic acids to glycoproteins, called
sialyltransferases.
The choice of ManNAc over other potential agents, including
puriﬁed sialic acid, for sialylation based therapeutics was deter-
mined by several factors (Chugh et al., 2012). Unlike NANA,
ManNAc has a neutral charge, which allows it to cross cell
membranes easily. Moreover, ManNAc is a naturally occurring
precursor molecule and is not incorporated directly at sialylation
sites, whereas NANA is the end product, and raising blood lev-
els of NANA to increase cellular uptake could theoretically affect
function of endothelial cell sialylated transmembrane proteins.
High plasma sialic acid levels have been noted in a variety of
disease states (Sillanaukee et al., 1999), but causality has not
been established. By contrast, ManNAc gets converted to NANA
inside cells where it is utilized for protein sialylation. Exogenously
administered ManNAc enter the sialic acid biosynthesis pathway
after the rate limiting step catalyzed by UDP–GNE (Figure 3),
thereby surmounting the intrinsic limitations of the pathway
during high demand states. Diseases involving the podocyte are
especially suited for ManNAc therapy for two reasons. Unlike
most other cells in the body, podocytes divide very infrequently,
which sets the stage for accumulation in these cells and conse-
quently lower oral dose requirement when compared to therapy
targeting dividing cells. Rapid urinary excretion after oral dos-
ing (90% loss of oral dose in urine by 4 h; Malicdan et al.,
2009) is also an advantage, since podocytes are exposed to most
of the oral dose while being ﬁltered through the glomerulus.
A combination of low dose requirement for podocyte disease
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FIGURE 3 | Sialic acid biosynthesis and recyclingpathway. In humans, sialic
acid is synthesized fromglucose.The rate limiting step, catalyzed byGNE, is
subject to feedback inhibition.ManNAc is the product of this rate limiting step,
so exogenousManNAc supplementation enters the pathway after this step.A
substantial amount of sialic acid is recycled via the anion transporter sialin
following lysosomal degradation of glycoproteins and glycolipids.
and rapid urinary excretion reduces overall chances of systemic
toxicity.
Based on our current experience, we would consider using
ManNAc for maintenance therapy in both diabetic nephropathy
and MCD, either as a daily very low dose regimen, or intermittent
low dose therapy. Even though long term glucocorticoid ther-
apy is associated with multi-organ complications, the ﬁrst episode
of MCD should still be treated with glucocorticoids, especially
in children, at least in part to prove that the disease is indeed
glucocorticoid sensitive. Also, glucocorticoids reduce podocyte
Angptl4 upregulation (Clement et al., 2011) and increase Angptl4
secretion from skeletal muscle, heart and adipose tissue (dis-
cussed later), both of which beneﬁt patients with MCD. Since
80–90% of children relapse after the ﬁrst remission (Koskimies
et al., 1982; Tarshish et al., 1997), ManNAc is perfectly suited
as a maintenance drug to reduce the frequency and intensity of
relapse. Glucocorticoids are not used in the treatment of diabetic
nephropathy, since they aggravate the underlying diabetic state.
RECOMBINANT ANGPTL4 MUTANTS FOR TREATMENT OF
DIABETIC NEPHROPATHY AND FSGS
A recent study published by our group shows how circulating
Angptl4 is an intrinsic component of nephrotic syndrome, and
functions in tandem with plasma albumin and free fatty acids
(FFAs) to link proteinuria with hypertriglyceridemia (Clement
et al., 2014). Albumin is the most abundant plasma protein that
circulates as a 69 kDa monomer, and serves as a vehicle to trans-
port cations, hormones, and FFA. FFA are a critical energy source
for the body, and also serve as an important molecular media-
tor in nephrotic syndrome. Organs like skeletal muscle and heart
utilize FFA for energy (Mattijssen and Kersten, 2012), while adi-
pose tissue recycles FFA, since it both releases and takes up FFA
for storage as triglycerides. Normal sources of fatty acids include
diet, mobilization from adipose tissue, and conversion of excess
carbohydrates into fat by the liver. Some fatty acids are coupled
with glycerol to form triglycerides (or triacylglycerols) for trans-
port or storage, and can be converted back into FFA by lipases. The
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FIGURE 4 | Schematic illustration of negative feedback loops in the
link between proteinuria, hypoalbuminemia and hypertriglyceridemia
mediated by Angptl4 and FFA (free fatty acids). Plasma FFA are
non-covalently bound to albumin, and because of the preferential loss of
albumin with low FFA content during proteinuria, albumin with higher FFA
content is retained in circulation. As glomerular disease progresses and
proteinuria increases, hypoalbuminemia develops, and the combination of
high albumin FFA content and lower plasma albumin levels increases the
plasma FFA/albumin ratio. This increased available FFA enters skeletal
muscle, heart and adipose tissue to induce upregulation of Angptl4, at least
in part mediated by PPARs. Angptl4 secreted from these organs
participates in two feedback loops. In the systemic loop, it binds to
glomerular endothelial αvβ5 integrin and reduces proteinuria, the principal
driver of nephrotic syndrome. In a local loop, it inhibits LPL activity in the
same organs from which it is secreted to reduce the uptake of FFA, thereby
curtailing the stimulus for its own upregulation. Exogenously administered
recombinant wild type Angptl4 affects both loops, similar to endogenous
Angptl4, thereby reducing proteinuria and increasing plasma triglyceride
levels. Recombinant mutant forms of Angptl4 bypass the local loop, and act
only on the systemic loop, thereby reducing proteinuria without raising
plasma triglyceride levels. Adapted from Clement et al. (2014).
rest circulate in blood as FFA,mostly coupled non-covalently with
albumin. Albumin molecules have six high afﬁnity FFA binding
sites, and many low afﬁnity binding sites, and up to ten FFA
molecules can be bound to an albumin molecule at any given
time (Papamandjaris et al., 1998). Adipose tissue releases FFA into
circulation after serial conversion of triglycerides to diglycerides by
adipose triglyceride lipase, and diglycerides to monoglycerides by
hormone sensitive lipase. After digestion of dietary fat, medium
chain fatty acids (8–12 carbon chain) are transported coupled
with albumin, whereas long chain fatty acids (14 or more car-
bon chain) are converted back to triglycerides, incorporated into
chylomicrons, and transferred to the circulation via the thoracic
duct.
Sources of FFA for uptake by organs includes albumin bound
FFA, and conversion of circulating triglycerides into FFA by the
endothelium anchored enzyme LPL. In nephrotic syndrome, the
balance between these two sources of FFA uptake is signiﬁcantly
altered. Proteinuric kidneys preferentially loose albumin with a
low FFA content, resulting in progressive retention of albumin
with high FFA content (Ghiggeri et al., 1987; Clement et al., 2014)
(Figure 4). As proteinuria reaches nephrotic range, hypoalbu-
minemia develops, and a combination of high FFA containing
albumin and hypoalbuminemia raises the plasma ratio of FFA
to albumin (Clement et al., 2014). This elevated plasma FFA
to albumin ratio drives increased FFA uptake in skeletal mus-
cle, heart and adipose tissue, which in turn increases Angptl4
expression and secretion from these tissues. Since Angptl4 is a
known peroxisome proliferator-activated receptor (PPAR) target
gene (Kersten et al., 2009; Staiger et al., 2009; Georgiadi et al.,
2010), and PPAR expression is increased during the nephrotic
phase in these tissues (Clement et al., 2014), at least part of this
Angptl4 upregulation is likely to be PPAR mediated. Angptl4
secreted from these organs into the circulation has two effects.
First, it binds to the αvβ5 integrin in glomerular endothelium and
reduces proteinuria (Figure 4, systemic feedback loop). The pre-
cise mechanism by which the Angptl4 – αvβ5 integrin interaction
reduces proteinuria is not known, but it is possible that addi-
tional feedback loops within the glomerulus are involved. Second,
Angptl4 inactivates LPL activity in these organs, thereby reduc-
ing the conversion of triglycerides into FFA, which reduces FFA
uptake by this pathway (Figure 4, local feedback loop), and also
results in hypertriglyceridemia. In summary, the retention of FFA
in nephrotic syndrome tends to accelerate production of Angptl4
from peripheral organs, whereas its own effect on LPL activity in
these same organs limits the extent of upregulation (Clement et al.,
2014).
In many ways, this attempt to reduce proteinuria by Angptl4
represents a systemic response against rising proteinuria. The local
feedback loop slowsdown this anti-proteinuric effect of circulating
Angptl4. Since this is a naturally occurring response in the body,
these pathways could be manipulated pharmacologically to attain
a prolonged anti-proteinuric effect in one of two ways. First, exist-
ing pharmacological agents could be used to increase the intrinsic
production of Angptl4 from skeletal muscle, heart and adipose tis-
sue. PPAR agonists (Mattijssen and Kersten, 2012), β2-adrenergic
receptor agonists (Mattijssen and Kersten, 2012), glucocorticoids
(Koliwad et al., 2009), and FFA supplementation (Clement et al.,
2014) increase Angptl4 expression in these organs. This may
contribute to the partial efﬁcacy of glucocorticoids in different
diseases that cause nephrotic syndrome, since they are a compo-
nent of most existing treatment regimens. This approach, however,
has limitations, since increasing intrinsic Angptl4 production in
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these organs will activate both systemic and local feedback loops,
worsen hypertriglyceridemia and potentially reduce the uptake of
FFA, a major source of energy, into skeletal muscle and heart,
causing end organ dysfunction. Moreover, PPAR agonists and
glucocorticoids have very signiﬁcant toxicities due to effects on
multiple pathways.
Another way to manipulate this naturally occurring pathway
is to use recombinant human Angptl4, which would be supe-
rior to the agents mentioned above, since both therapeutic and
side effects will be selective for this protein (Figure 4). Since
native recombinant human Angptl4 in circulation will have the
same limitations as tissue secreted Angptl4, it is appropriate
to modify the protein to ignore the local feedback loop (“the
brake”), while acting solely on the systemic feedback loop (“the
accelerator”). This would allow for achieving higher circulating
Angptl4 levels than otherwise possible by using existing agents,
without incurring the risk of hypertriglyceridemia or starving
skeletal muscle and heart of energy substrate. Since population
based studies (Romeo et al., 2007; Romeo et al., 2009) show that
individuals carrying the E40K variant have very low triglyceride
levels and reduced ability of Angptl4 to inhibit LPL in vitro
(Yin et al., 2009), we developed recombinant mutant forms of
human Angptl4 with changes at amino acid 40 or its neighbor
amino acid 39 (Figure 5). Also, since Angptl4 readily cleaves
between amino acids 161 to 164, we made additional changes
in this region to improve the half-life of the intact protein. Stud-
ies with recombinant rat Angptl4 have shown the formation of
very high order oligomers that migrate even slower than α2-
macroglobulin (720 kDa) on one-dimensional non-reducing gels
(Clement et al., 2011). This feature, combined with the ability
FIGURE 5 | (A) Schematic representation of wild type and mutant human
Angptl4 proteins showing mutations in areas important for LPL binding
(amino acid 40, and adjacent amino acid 39) and protein cleavage (amino acids
161 to 164). (B)Western blot of recombinant tagged proteins using mouse
anti V5 antibody to demonstrate the expected size of the intact protein and
reduced cleavage in the mutant proteins (arrows). (C) Plasma levels of wild
type (8525) or mutant (8501, 8515) human Angptl4 in Buffalo Mna rats (n = 3
rats/group) after injecting 55 μg of recombinant human protein as assessed
by OD 450 using reagents from the human Angptl4 ELISA kit. (D) Effect of
injecting wild type and mutant Angptl4 on proteinuria in Buffalo Mna rats.
(E) Effect of injecting wild type and mutant Angptl4 on plasma triglyceride
levels in Buffalo Mna rats. (F) Plasma levels of wild type (8525) and mutant
(8496, 8520) human Angptl4 proteins as assessed by OD 450 after injecting a
lower dose (15 μg) in Zucker Diabetic Fatty (ZDF) rats (n = 4 rats/group). (G)
Effect of injecting wild type and mutant Angptl4 on proteinuria in ZDF rats.
(H) Effect of 15 μg of wild type and mutant Angptl4 on plasma triglyceride
levels in ZDF rats. Error bars are s.e.m. t -test, two way, *P < 0.05,
**P < 0.01. In panel D, black * are shown where all three study groups were
individually different from control injected rats. In panels D, e.g., colored *
shown where individual values were signiﬁcantly different from corresponding
baseline values. # in panel E is P < 0.05 in mutant protein groups compared
to wild type Angptl4 injected rats. Adapted from Clement et al. (2014).
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of Angptl4 to bind HDL particles in circulation (Mandard et al.,
2006), helps prolong its half-life in circulation in the setting of
nephrotic syndrome, in which non-oligomerizing proteins like
albumin and IgG are readily lost in urine. Wild type human and
six different Angptl4 mutant clones and their HEK 293 based
stable cell lines were developed and tested (Chugh, 2011a). Pub-
lished work on the wild type and four of these mutants (Clement
et al., 2014) (Figures 5A–H), including pharmacokinetic stud-
ies in nephrotic rats, show that mutagenesis did not reduce the
ability to reduce proteinuria in Buffalo Mna rats (a model of
FSGS) and Zucker diabetic fatty rats (ZDF, a model of diabetic
nephropathy). Some of the mutant proteins reduced protein-
uria more substantially and for a longer duration than the wild
type protein (Figures 5D,G). Plasma triglyceride levels increased
with the wild type, but not the mutant proteins. A single 55 μg
dose of recombinant human Angptl4 reduced proteinuria for over
2 weeks, with peak reduction of up to 65% in Buffalo Mna rats
(Figure 5D). Finally, a smaller dose (15 μg) of wild type recom-
binant Angptl4 in ZDF rats reduced proteinuria without causing
hypertriglyceridemia (Figure 5G), suggesting a lower threshold
for Angptl4 to act via the systemic loop, compared to the local
feedback loop. These recombinant proteins are now being pro-
duced on a large scale to allow for expanded testing and prolonged
administration in nephrotic rats to study effects on chronic kid-
ney disease. Since Angptl4 is a normal circulating protein with
levels that vary several fold with fasting / feeding, the likelihood
of major aberrant side effects of therapy with mutant Angptl4
protein is relatively low. However, like any mutated protein used
for therapeutics, there is a potential for developing an antibody
response in some patients that may limit long term usage in these
patients.
In summary, sialylation based and recombinant mutated
Angptl4 based therapeutic strategies hold signiﬁcant promise in
the treatment of common forms of proteinuric chronic kidney
disease, including diabetic nephropathy. Both areas are novel,
protected by intellectual property, innovative, mechanism based,
and have been extensively studied in vivo in appropriate human
disease models. Moreover, the central role played by Angptl4 in
nephrotic syndrome (at par in importance with albumin, FFA
and triglycerides) suggests that manipulating Angptl4 related
pathways in the context of therapeutics has a high chance of
success.
PERSPECTIVE ON FUTURE DEVELOPMENT OF ADDITIONAL
NOVEL THERAPIES
The discovery of Angptl4 as a major player in human nephrotic
syndrome was based on a strategy to identify and selectively
investigate genes/ proteins that could potentially link at least
two of the three major components (proteinuria, hyperlipidemia,
and edema) of nephrotic syndrome. This approach continues to
have potential in the future, since the pathogenesis of hyper-
cholesterolemia, proteinuria, and increase peripheral capillary
permeability related to edema are not completely understood.
Also, the reason for the muted response of the liver to counter
hypoalbuminemia in nephrotic syndrome by increasing albumin
synthesis in most patients is unclear. In developing future thera-
pies, it is important to steer clear of old unyielding hypotheses,
like Shalhoub’s hypothesis of putative T-cell secreted factors as the
causal mediator of MCD, or the charge hypothesis of glomerular
permeability to explain selective proteinuria. Investigators must
classify early footprints of glomerular disease based on molecular
changes, rather than current morphology based standards. In this
context, selective proteinuria could be better explained by looking
for uniformity of early molecular changes in the glomerulus in
MCD, whereas non-selective proteinuria potentially attributable
to presence onnon-uniformearly changes in other diseases. Unless
an objective and goal directed approach is adopted toward devel-
oping modern therapeutics, future nephrologists may have to
continue to adapt drugs developed for non-kidney indications to
treat kidney disease.
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